Obinutuzumab + Bendamustine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Indolent Non-hodgkin Lymphoma
Conditions
Indolent Non-hodgkin Lymphoma
Trial Timeline
Dec 12, 2017 → Dec 31, 2022
NCT ID
NCT03492775About Obinutuzumab + Bendamustine
Obinutuzumab + Bendamustine is a phase 2 stage product being developed by Roche for Indolent Non-hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03492775. Target conditions include Indolent Non-hodgkin Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03492775 | Phase 2 | Completed |
| NCT01059630 | Phase 3 | Completed |
Competing Products
15 competing products in Indolent Non-hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Linperlisib ； Rituximab | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| GP2013 | Novartis | Phase 1 | 33 |
| Ibrutinib + GA 101 | Roche | Phase 2 | 52 |
| Placebo + Rituximab + Idelalisib | Gilead Sciences | Phase 3 | 76 |
| Idelalisib | Gilead Sciences | Phase 1/2 | 40 |
| Idelalisib + Rituximab + Bendamustine + Placebo | Gilead Sciences | Phase 3 | 76 |
| Idelalisib + Rituximab + Bendamustine + Ofatumumab + Fludarabine + Everolimus + Bortezomib + Chlorambucil + Lenalidomide | Gilead Sciences | Phase 1 | 32 |
| IBI376 | Innovent Biologics | Phase 2 | 51 |
| Copanlisib + Nivolumab + Rituximab | Bristol Myers Squibb | Phase 1 | 32 |
| SAR245409 | Sanofi | Phase 1 | 32 |
| Copanlisib (BAY80-6946) | Bayer | Pre-clinical | 20 |
| Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2 | Lundbeck | Phase 3 | 74 |
| Bezuclastinib | Cogent Biosciences | Pre-clinical | 20 |